Core Viewpoint - Synthetic biology is a multidisciplinary field that integrates biology, informatics, genomics, and chemistry to design and construct artificial biological systems, marking a significant leap from understanding life to designing it, often referred to as the third biotechnology revolution [7][11]. Summary by Sections Synthetic Biology Overview - Synthetic biology involves the engineering of biological systems to produce valuable products through modified chassis cells that express specific genes to obtain target products [7][9]. - The core principles of synthetic biology include standardization, decoupling, and modularization, which facilitate the design and construction of biological systems [8][9]. Market Growth and Trends - The global synthetic biology market is projected to grow at a CAGR of 24%, reaching approximately $18.885 billion by 2024 [16][19]. - The healthcare sector is expected to be the largest segment, with a market size of $5.022 billion by 2024, accounting for 26.6% of the overall market [19]. Technological Advancements - Advances in gene sequencing, editing, and synthesis technologies have significantly reduced costs and barriers to entry in synthetic biology, enabling rapid development and iteration of engineered organisms [39][40]. - The integration of AI and big data in molecular design is accelerating the development of synthetic biology applications [39]. Applications and Benefits - Synthetic biology can replace traditional chemical synthesis or natural extraction methods, improving production economics and environmental sustainability [29][33]. - The technology allows for the production of a wide range of products, including pharmaceuticals, chemicals, and biofuels, using renewable resources and reducing reliance on fossil fuels [35][36]. Investment and Policy Support - There has been a surge in investment in synthetic biology, with global financing reaching $18 billion in 2021, nearly doubling from previous years [44]. - Governments in the U.S. and China are prioritizing synthetic biology in their strategic plans, recognizing its potential for innovation and economic growth [42][43].

Core Viewpoint - The luxury goods industry is increasingly focusing on the commercialization of rare materials, including synthetic leather made from extinct species, to enhance exclusivity and sustainability [1][2][6]. Group 1: New Material Development - A new type of leather, created using synthetic biology techniques to replicate dinosaur skin, is expected to enter the market by the end of this year [3][5]. - The technology for this leather is developed by BSF Enterprise PLC's subsidiary, Lab-Grown Leather Ltd., in collaboration with VML and The Organoid Company, utilizing DNA from extinct species like Tyrannosaurus rex [5][6]. Group 2: Product Characteristics and Market Strategy - The dinosaur leather is anticipated to possess qualities superior to modern leather, such as increased durability and wear resistance [6]. - Initial applications will focus on accessories, with a flagship luxury fashion item targeted for launch by the end of 2025, followed by potential expansion into other sectors like the automotive industry [6]. Group 3: Production Methodology - Lab-Grown Leather Ltd. employs a unique "scaffold-free" tissue engineering technique, allowing cells to construct natural structures without additives, resulting in a product that closely resembles traditional leather [7]. - This method produces leather that is flawless, wrinkle-free, and scar-free, significantly reducing waste during production [7].

Group 1 - The article highlights the growing attention and support for synthetic biology, biomanufacturing, and the bio-industry from various sectors including government, academia, and investment, with many local governments incorporating synthetic biological manufacturing into their work reports [1] - The upcoming third SynBio Suzhou conference will take place on August 1-2, 2025, at the Suzhou International Expo Center, covering topics such as agriculture, food, energy, medical aesthetics, pharmaceuticals, and health [3] - The seventh CMC-China Expo is expected to attract 20,000 attendees, featuring 450 exhibiting companies and 600 invited guests, with multiple forums and a dedicated synthetic biology exhibition area [16] Group 2 - The article lists notable past guests and speakers from various institutions and companies, indicating a diverse representation of expertise in the field of synthetic biology [4][7][9] - The event aims to gather scientists, entrepreneurs, and investors to collaborate and discuss the future of synthetic biology and its applications [2][3] - The article emphasizes the importance of industry collaboration and innovation in advancing synthetic biology and biomanufacturing [1][26]

Group 1 - The article highlights the growing attention and support for synthetic biology, biomanufacturing, and the bio-industry from various sectors including government, academia, and investment, with many local governments incorporating synthetic biological manufacturing into their work reports [1] - The upcoming third SynBio Suzhou conference will take place on August 1-2, 2025, at the Suzhou International Expo Center, covering topics such as agriculture, food, energy, medical aesthetics, pharmaceuticals, and health [3] - The seventh CMC-China Expo is expected to attract 20,000 attendees, featuring 450 exhibiting companies and 600 invited guests, with multiple forums and a dedicated synthetic biology exhibition area [16] Group 2 - The article lists notable past guests from various institutions and companies, indicating a diverse representation of expertise in the field of synthetic biology and biomanufacturing [4][7][9] - The conference aims to gather scientists, entrepreneurs, and investors to collaborate and discuss the future of synthetic biology, emphasizing the importance of industry collaboration [2][3] - The article encourages participation in the conference by offering free registration for attendees, highlighting the event's accessibility to a broader audience [13][14]

融行业智慧、共襄盛举 聚产业力量、擘画未来 第三届SynBio Suzhou中国合成生物学"科学家+企业家+投资家"大会 将于2025年8月1-2日在 苏州 国际博览中心 举办（同期举办 第七届CMC-China博览会 ）！ 扫码！锁定免费参会名额！ 话题将覆盖： 农业、食品与能源， 医美、医药、大健康 ， 合成生物技术、中试放大与商业化， 以 及 项目路演 等多个方面，诚邀莅临，共襄盛举！ 往期精彩： 作为新质生产力的代表，合成生物学、生物制造以及生物产业，近些年，受到来自政产学研用金各 方广泛关注和重点支持，多地政府将合成生物制造产业写进工作报告。 科学家、企业家和投资家， 在产业发展中发挥着重要作用。 常珊 江苏理工学院 生物信息与医药工程 研究所所长 大会主办丨 Synbio深波 会议时间 | 2025年8月1-2日 会议地点 | 中国·苏州·国际博览中心B馆 扫码！锁定免费参会名额！ 圆满落幕！下一站去哪？2023中国（苏州）合成生物学创新峰会成功 举办 2023中国(苏州)合成生物学产业技术峰会圆满落幕 合成生物，聚势苏州：2024中国合成生物学"科学家+企业家+投资 家"大会圆满召开！ 往期嘉宾 ...

Core Viewpoint - The collaboration between Bio Island Laboratory and Wanhua Chemical aims to innovate in the field of bio-based materials, positioning both entities as leaders in the industry [1][2]. Group 1: Collaboration and Innovation - Bio Island Laboratory and Wanhua Chemical signed an agreement to establish the "Bio Island Laboratory-Wanhua Chemical Bio-Chemical Research and Manufacturing Innovation Consortium" [1]. - The partnership focuses on continuous innovation in bio-based materials and aims to lead the direction of industry development [1][2]. - The collaboration is part of a broader initiative to create a "government-industry-university-research-finance-application" ecosystem to accelerate the transformation of scientific achievements into productive forces [2]. Group 2: Industry Insights - The bio-manufacturing industry is projected to reach a value of approximately $30 trillion, making it a strategic area of competition among countries [2]. - Guangzhou's government is committed to supporting the transformation of scientific achievements and fostering innovation in the bio-economy, aiming to secure a strategic position in the future of this sector [2]. Group 3: Related Developments - The National Development and Reform Commission has included multiple projects related to bio-based materials and biofuels [5]. - Companies like Lianlong are leveraging synthetic biology to develop high-performance materials, indicating a trend towards innovation in polymer materials [5]. - A startup in synthetic biology has raised $6.7 million in seed funding to advance applications in protein fibers, showcasing the growing interest and investment in this field [5].

Core Insights - The company aims to enhance its market competitiveness in the food, nutrition, and beauty sectors by investing in Peisheng Biotechnology to promote the application of new raw materials in consumer products [1][2] - The establishment of Beijing Kaiyuan Juliy aims to leverage the capital and talent resources in the capital city to improve the company's professional capabilities in business expansion and capital operations, driving a dual strategy of "industry + capital" [1] Product Pricing and Market Strategy - The sales prices of products such as erythritol, blended sugars, and allulose will fluctuate based on specifications, business conditions, and market competition, with a dynamic adjustment throughout the year [1] - The company has a competitive edge in production technology and cost control for tagatose, which is currently in an active promotion phase, with market pricing being continuously optimized based on market feedback [1] New Product Development - The company is committed to innovation-driven growth, focusing on synthetic biology and advancing new product research and industrialization [2] - A new 10,000-ton production line for allulose is under rapid construction, aiming to secure a first-mover advantage in the fast-growing market once approved for domestic use [2] - The existing 85,000-ton erythritol production line is undergoing upgrades to enable flexible manufacturing capabilities across multiple products, significantly reducing new product line construction costs and enhancing market responsiveness [2] - The company is optimizing production processes for high-activity biological raw materials like glycerol glycosides and sweet tea glycosides, with plans for small-scale production based on technology maturity and market demand [2]

Core Viewpoint - The petrochemical industry is undergoing significant transformation, with a focus on technology-driven quality and efficiency improvements in new capacity additions, highlighting opportunities in high-end and differentiated markets such as new materials and fine chemicals [1] Group 1: Role of Engineering Construction Enterprises - Engineering construction enterprises should emphasize innovation leadership to seize new market opportunities and inject strong momentum into sustainable development [1] - The enterprises need to enhance their technological innovation capabilities and establish a comprehensive innovation system focused on results transformation [1] - There is a need to explore core technologies related to energy transition and prioritize research on high-performance polymer materials and biomanufacturing as part of a "second growth curve" [1] Group 2: Innovation Platforms and Digital Development - Engineering construction enterprises should establish platforms for technology policy research, pilot verification, and technology application to facilitate the industrialization of technological achievements [2] - Collaboration with universities, research institutions, and enterprises is essential to integrate various technological verification resources and promote technology sourcing and transformation [2] - The enterprises must advance digital and intelligent development, enhancing information management and integrating artificial intelligence into business processes to create exemplary models in the engineering construction sector [2]

结果显示，在取自石油炼化厂和氯碱化工厂的高盐废水中，该菌株仅需2天即可净化其中同时存在 的5种有机污染物。 这项研究成功开发了基于需钠弧菌的复合污染物工程菌构建平台，实现了从代谢通路的挖掘、设计 和合成到单一、复合污染物降解菌株的构建、测试，以及在实际工业废水样本处理应用的全流程，为石 化、氯碱等高盐废水处理、海上石油泄漏、微塑料污染等全球性挑战提供了生物解决方案。同时， INTIMATE技术为多基因簇工程底盘的构建提供了通用技术平台，使得同一菌株中多种代谢功能的整合 以及优质菌种的迭代功能拓展成为可能，可扩展至其他污染物降解体系的构建乃至天然产物合成、高值 化学品细胞工程构建等合成生物学应用场景。 5月7日，上海交通大学生命科学技术学院、微生物代谢全国重点实验室唐鸿志团队与中国科学院深 圳先进技术研究院/中国农业科学院深圳农业基因组研究所（岭南现代农业科学与技术广东省实验室深 圳分中心）戴俊彪团队合作，在《自然》上在线发表研究成果论文，这项研究用合成生物学方法构建了 需钠弧菌工程菌株，能在高盐工业废水和高盐土壤中同时降解多种有机污染物，为解决石化废水排污、 海洋石油泄漏等全球性环境问题提供了全新的技术方案。 ...

Industry Overview - The pesticide industry in 2024 is under pressure but maintains stable development due to food security demands, showcasing trends in technological innovation and green transformation [2] - China, as the largest pesticide producer and exporter, is seeing an increase in technical capabilities and product variety, with top domestic companies experiencing revenue growth [2] - The upcoming "one certificate, one product" policy is expected to enhance industry standardization and sustainable development [2] Product Pricing and Trends - Current prices for key products are: - Abamectin: 515,000 CNY/ton - Methomyl: 720,000 CNY/ton - Bacillus thuringiensis: 27,000 CNY/ton - Prices are expected to rise, influenced by raw material costs and seasonal demand [3] Core Competencies - The company has strong resilience during industry downturns and has initiated cost-reduction strategies [3] - Production capacity includes: - Active ingredient capacity: 110,200 tons - Formulation capacity: 132,700 tons - The company holds 296 domestic pesticide registrations and 2,770 overseas registrations, indicating a robust product structure [3][5] Strategic Planning for 2025 - Focus on quality and cost efficiency for key products like Abamectin and Methomyl [6] - Enhance brand influence and market presence through new marketing strategies [6] - Accelerate international expansion, particularly in South America and Southeast Asia [6][8] - Drive research and development efficiency, emphasizing innovative product development [6] Financial Performance - In 2024, the company reported: - Revenue: 4.237 billion CNY, a 0.32% increase - Net profit: 81.36 million CNY, a 31.11% increase - Non-recurring net profit: 51.18 million CNY, a 12.52% increase [10] R&D and Innovation - The company is a pioneer in the industrial development of Abamectin and Methomyl, with a comprehensive product chain [5][13] - In 2024, the company established a synthetic biology laboratory to enhance product development capabilities [7][13] - New product projects are progressing, with 15 new patents granted in 2024 [8] Market Expansion and Risk Management - International revenue accounts for 33.89%, primarily from South America, Southeast Asia, and Africa [11] - The company employs financial derivatives to hedge against foreign exchange risks [11] - The impact of the US-China tariff conflict is minimal, with less than 2% of exports affected [16]